Bionomics has bought the assets of Prestwick Chemical to broaden its drug portfolio and take over the company’s supply of chemistry services to giants like GlaxoSmithKline and Bayer.
Early stage drug developer Bionomics has bought the assets of a French rival Prestwick Chemical to broaden its drug portfolio and take over the company’s supply of services to pharmaceutical giants like GlaxoSmithKline and Bayer.
Chief executive Deborah Rathjen said the company pounced in a “firesale" after Prestwick entered administration.
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
